- Home
- PRK vs CGON Comparison
PRK vs CGON Comparison
Compare PRK & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRK
- CGON
- Stock Information
- Founded
- PRK 1908
- CGON 2010
- Country
- PRK United States
- CGON United States
- Employees
- PRK N/A
- CGON N/A
- Industry
- PRK Major Banks
- CGON
- Sector
- PRK Finance
- CGON
- Exchange
- PRK Nasdaq
- CGON NYSE
- Market Cap
- PRK 2.6B
- CGON 2.1B
- IPO Year
- PRK N/A
- CGON 2024
- Fundamental
- Price
- PRK $174.88
- CGON $27.20
- Analyst Decision
- PRK Hold
- CGON Strong Buy
- Analyst Count
- PRK 1
- CGON 10
- Target Price
- PRK $170.00
- CGON $64.44
- AVG Volume (30 Days)
- PRK 65.2K
- CGON 811.0K
- Earning Date
- PRK 07-21-2025
- CGON 08-07-2025
- Dividend Yield
- PRK 2.45%
- CGON N/A
- EPS Growth
- PRK 23.42
- CGON N/A
- EPS
- PRK 9.75
- CGON N/A
- Revenue
- PRK $515,788,000.00
- CGON $662,000.00
- Revenue This Year
- PRK $7.96
- CGON N/A
- Revenue Next Year
- PRK $3.31
- CGON $25,206.93
- P/E Ratio
- PRK $17.90
- CGON N/A
- Revenue Growth
- PRK 10.66
- CGON 224.51
- 52 Week Low
- PRK $137.97
- CGON $14.80
- 52 Week High
- PRK $207.99
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- PRK 68.88
- CGON 56.82
- Support Level
- PRK $174.05
- CGON $25.81
- Resistance Level
- PRK $179.48
- CGON $27.28
- Average True Range (ATR)
- PRK 3.46
- CGON 1.00
- MACD
- PRK 1.25
- CGON 0.00
- Stochastic Oscillator
- PRK 87.76
- CGON 83.08
About PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.